Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% ...

BOSTON and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and ...

Rapport Therapeutics Inc. added $20 million to its cash runway for its lead phase III oral seizure drug, RAP-219, through a potential $328 million license deal signed with Tenacia Biotechnology Co.

BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and ...